Cancer Peptide Vaccine Drives Killer T-Cells Into Esophageal Tumors and May Boost Immunotherapy Response
A five-peptide cancer vaccine induced tumor-specific killer T-cells that infiltrated esophageal tumors in all 15 patients, while upregulating PD-1/PD-L1 — suggesting synergy with checkpoint immunotherapy.
Quick Facts
What This Study Found
The cancer peptide vaccine S-588410 — containing five HLA-A*24:02-restricted peptides derived from cancer testis antigens — successfully induced tumor-specific immune responses in all 15 esophageal cancer patients. After vaccination, tumor tissue showed increased densities of CD8+ T-cells, CD8+ granzyme B+ cells (indicating active killing), and CD8+ PD-1+ cells. PD-L1 expression also increased in the tumor microenvironment.
Critically, the same peptide-specific T-cell receptor sequences were found in both blood and tumor tissue after vaccination, confirming that the vaccine-induced killer T-cells actually infiltrated the tumors. The upregulation of PD-1 and PD-L1 after vaccination suggests that combining S-588410 with checkpoint inhibitors (anti-PD-1/PD-L1 antibodies) could further enhance its anti-cancer effect.
Key Numbers
n=15 patients · 5-peptide vaccine · Median 5 doses · CTL response in 100% for ≥1 peptide · 80% had treatment-related AEs · Injection site reactions: grade 1 (n=1), grade 2 (n=11)
How They Did This
This was an exploratory open-label clinical study in 15 HLA-A*24:02-positive esophageal cancer patients. S-588410 was administered subcutaneously emulsified with MONTANIDE ISA51VG adjuvant (median 5 doses). Researchers analyzed pre- and post-vaccination tumor tissue for immune cell densities (CD8+, granzyme B+, PD-1+, PD-L1+) using immunohistochemistry. CTL responses were assessed in blood, and peptide-specific T-cell receptor sequencing was performed on both tumor tissue and blood samples.
Why This Research Matters
Cancer peptide vaccines have long been pursued as a way to train the immune system to specifically target cancer cells. This study provides direct evidence that a peptide vaccine can successfully drive tumor-infiltrating lymphocytes into esophageal tumors — and reveals that the resulting immune response upregulates PD-1/PD-L1, providing a biological rationale for combining peptide vaccines with immune checkpoint inhibitors. This combination strategy could make both therapies more effective.
The Bigger Picture
Cancer peptide vaccines have been studied for decades with mixed clinical results. A key challenge has been proving that vaccine-induced T-cells actually reach and infiltrate tumors. This study provides that proof through T-cell receptor sequencing — showing the same vaccine-specific T-cells in both blood and tumor tissue. The PD-1/PD-L1 finding is particularly significant because it suggests why peptide vaccines alone have had limited success: the tumors mount a counter-defense through checkpoint pathways. Combining vaccines with checkpoint inhibitors could overcome this barrier, representing a new paradigm in cancer immunotherapy.
What This Study Doesn't Tell Us
This is an open-label exploratory study with only 15 patients and no control group, making it impossible to attribute clinical benefit to the vaccine. The study focused on immunological endpoints rather than tumor response or survival. Only HLA-A*24:02-positive patients were eligible, limiting applicability. The MONTANIDE adjuvant may contribute to the high rate of injection site reactions.
Questions This Raises
- ?Will combining S-588410 with anti-PD-1/PD-L1 checkpoint inhibitors produce measurable tumor responses in esophageal cancer?
- ?Can similar multi-peptide vaccine approaches be developed for other HLA types to expand eligibility beyond A*24:02 patients?
- ?Does the degree of tumor-infiltrating lymphocyte increase after vaccination correlate with clinical outcomes?
Trust & Context
- Key Stat:
- 100% CTL response All 15 patients developed cytotoxic T-lymphocyte responses to at least one of the five vaccine peptides, and the same T-cell receptors were confirmed in both blood and tumor tissue
- Evidence Grade:
- This is a small exploratory open-label clinical study (n=15) without a control group, designed to investigate immunological mechanisms rather than clinical efficacy. While the immunological findings are compelling, the evidence is preliminary and cannot demonstrate clinical benefit.
- Study Age:
- Published in 2020, this study represents an important proof-of-concept for cancer peptide vaccines in esophageal cancer. Subsequent combination studies with checkpoint inhibitors may have been initiated based on these findings.
- Original Title:
- Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
- Published In:
- Cancer immunology, immunotherapy : CII, 69(11), 2247-2257 (2020)
- Authors:
- Daiko, H, Marafioti, T, Fujiwara, T, Shirakawa, Y, Nakatsura, T, Kato, K, Puccio, I, Hikichi, T, Yoshimura, S, Nakagawa, T, Furukawa, M, Stoeber, K, Nagira, M, Ide, N, Kojima, T
- Database ID:
- RPEP-04751
Evidence Hierarchy
Frequently Asked Questions
How does a cancer peptide vaccine work?
Cancer peptide vaccines contain small protein fragments (peptides) that match proteins found on cancer cells but not on healthy cells. When injected, these peptides train the immune system's killer T-cells to recognize and attack cells displaying those specific proteins. Unlike traditional vaccines that prevent disease, cancer vaccines aim to treat existing cancer by directing the immune system against it.
Why might combining this vaccine with checkpoint inhibitors work better?
The vaccine successfully pushed killer T-cells into tumors, but those tumors responded by increasing PD-1 and PD-L1 — molecular 'off switches' that tell T-cells to stop attacking. Checkpoint inhibitor drugs block these off switches. So combining the vaccine (which brings T-cells to the tumor) with checkpoint inhibitors (which prevent the tumor from shutting them down) could produce a much stronger anti-cancer response.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04751APA
Daiko, H; Marafioti, T; Fujiwara, T; Shirakawa, Y; Nakatsura, T; Kato, K; Puccio, I; Hikichi, T; Yoshimura, S; Nakagawa, T; Furukawa, M; Stoeber, K; Nagira, M; Ide, N; Kojima, T. (2020). Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.. Cancer immunology, immunotherapy : CII, 69(11), 2247-2257. https://doi.org/10.1007/s00262-020-02619-3
MLA
Daiko, H, et al. "Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.." Cancer immunology, 2020. https://doi.org/10.1007/s00262-020-02619-3
RethinkPeptides
RethinkPeptides Research Database. "Exploratory open-label clinical study to determine the S-588..." RPEP-04751. Retrieved from https://rethinkpeptides.com/research/daiko-2020-exploratory-openlabel-clinical-study
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.